Synergistic caspase-dependent apoptosis in combination with BET inhibitor (I-BET151) in patient-derived vemurafenib-resistant BRAFV600E melanoma cells, induction of pro-apoptotic BIM and suppression of anti-apoptotic Bcl-2, Bcl-XL, and XIAP, inhibition of YAP1 and AKT, prolonged survival associated with tumor growth inhibition in mice with patient-1-post BRAFV600E melanomas. Here, BCL2L1 is linked to melanoma.